B. Julie Feder's Insider Trades & SAST Disclosures
B. Julie Feder's most recent trade in Aura Biosciences Inc was a trade of 25,131 Common Stock done at an average price of $12.0 . Disclosure was reported to the exchange on Oct. 18, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern B. Julie Feder.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aura Biosciences Inc | Julie B. Feder | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.03 per share. | 18 Oct 2024 | 25,131 | 134,276 | - | 12.0 | 302,361 | Common Stock |
| Aura Biosciences Inc | Julie B. Feder | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.74 per share. | 18 Oct 2024 | 17,500 | 151,776 | - | 2.7 | 47,950 | Common Stock |
| Aura Biosciences Inc | Julie B. Feder | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 17,500 | 68,257 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Julie B. Feder | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 5,000 | 120,547 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Julie B. Feder | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.48 per share. | 18 Oct 2024 | 5,000 | 159,407 | - | 5.5 | 27,400 | Common Stock |
| Aura Biosciences Inc | Julie B. Feder | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 2,631 | 32,359 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Julie B. Feder | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.25 per share. | 18 Oct 2024 | 2,631 | 154,407 | - | 4.3 | 11,182 | Common Stock |
| Aura Biosciences Inc | Feder Julie B. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 103,715 | 103,715 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Feder B. Julie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 71,285 | 134,276 | - | 0 | Common Stock | |
| Aura Biosciences Inc | B. Julie Feder | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.64 per share. | 23 Jan 2024 | 6,609 | 62,991 | - | 7.6 | 50,521 | Common Stock |
| Aura Biosciences Inc | Julie B. Feder | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Julie B. Feder | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 48,750 | 72,985 | - | 0 | Common Stock | |
| Aura Biosciences Inc | Julie B. Feder | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.45 per share. | 31 Oct 2022 | 2,015 | 24,235 | - | 12.5 | 25,090 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges